Morgan Stanley Reiterates Overweight on Silence Therapeutics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz reiterated an Overweight rating on Silence Therapeutics (NASDAQ:SLN) and maintained a $20 price target.
June 26, 2023 | 1:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley analyst Michael Ulz reiterated an Overweight rating on Silence Therapeutics (NASDAQ:SLN) and maintained a $20 price target.
The Overweight rating from Morgan Stanley indicates a positive outlook for Silence Therapeutics. The maintained $20 price target suggests that the analyst believes the stock has potential for growth in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100